newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal,